NCI Community Oncology Research Program Clinical Trials

Titlesort descending Intervention NCT ID Sponsor Status
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and... Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo NCT03578081 Alliance for Clinical Trials in Oncology Recruiting
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2... Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment NCT03633331 Alliance for Clinical Trials in Oncology Active, not recruiting
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil Donepezil 5 mg, Placebo NCT02822573 Wake Forest University Health Sciences Recruiting
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... Endocrine therapy interruption NCT02308085 International Breast Cancer Study Group Active, not recruiting
Radiation Therapy in Treating Patients With Prostate Cancer 36.25 Gy IMRT, 51.6 Gy IMRT NCT01434290 Radiation Therapy Oncology Group Active, not recruiting
Reproductive Health Program in Patients With Cancer educational intervention, questionnaire administration, quality-of-life assessment NCT01806129 Eastern Cooperative Oncology Group Recruiting
S0820, Adenoma and Second Primary Prevention Trial Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac NCT01349881 Southwest Oncology Group Recruiting
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and... therapeutic conventional surgery, gastrointestinal complications management/prevention, quality-of-life assessment NCT02270450 Southwest Oncology Group Active, not recruiting
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration NCT02728596 Southwest Oncology Group Active, not recruiting
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast... Carvedilol, Laboratory Biomarker Analysis, Patient Observation NCT03418961 Southwest Oncology Group Recruiting

Pages